Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares traded down 5% during mid-day trading on Wednesday . The company traded as low as $65.79 and last traded at $65.87, with a volume of 470,833 shares changing hands. The stock had previously closed at $69.36.

A number of research analysts recently issued reports on the company. Morgan Stanley restated a “hold” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, June 8th. JMP Securities reiterated a “buy” rating and set a $84.00 price target (up previously from $80.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, June 8th. Jefferies Group reiterated a “buy” rating and set a $109.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, June 8th. Zacks Investment Research lowered Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Thursday, April 28th. Finally, Credit Suisse Group AG reiterated a “buy” rating and set a $101.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, May 25th. Three investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $99.10.

The stock has a 50 day moving average price of $60.03 and a 200 day moving average price of $61.82. The company’s market cap is $2.53 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.46) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.02. During the same period last year, the business earned ($0.83) earnings per share. On average, equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post ($5.93) EPS for the current fiscal year.

In related news, insider Sunil Agarwal sold 649 shares of the firm’s stock in a transaction on Thursday, July 21st. The stock was sold at an average price of $52.68, for a total transaction of $34,189.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Emil D. Kakkis sold 20,000 shares of the firm’s stock in a transaction on Friday, July 15th. The shares were sold at an average price of $50.85, for a total value of $1,017,000.00. Following the sale, the chief executive officer now directly owns 513,597 shares of the company’s stock, valued at $26,116,407.45. The disclosure for this sale can be found here.

A number of large investors have added to or reduced their stakes in the stock. Trexquant Investment LP acquired a new stake in Ultragenyx Pharmaceutical during the fourth quarter worth $1,010,000. Dimensional Fund Advisors LP boosted its stake in Ultragenyx Pharmaceutical by 9.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 57,172 shares of the biopharmaceutical company’s stock worth $6,414,000 after buying an additional 5,139 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its stake in Ultragenyx Pharmaceutical by 8.1% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 153,788 shares of the biopharmaceutical company’s stock worth $17,252,000 after buying an additional 11,497 shares in the last quarter.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.